Endo, Glaxo to Settle Suits Over Testosterone Drug
- Suits blame testosterone booster for causing heart attacks
- Accord follows Lilly’s decision to resolve testosterone cases
Testim testosterone gel.
Photographer: Jacqueline Larma/AP Photo
This article is for subscribers only.
Endo Pharmaceuticals Inc. and GlaxoSmithKline LLC agreed to settle lawsuits accusing the drugmakers of hiding the health risks of a testosterone-boosting drug marketed to middle-aged men, according to court filings.
The terms of the tentative deal weren’t disclosed Friday, but the accord would resolve more than 1,300 suits filed by men who blame a drug manufactured by Endo and co-promoted by GSK for causing potentially fatal blood clots. The settlement doesn’t cover cases targeting AbbVie Inc., one of the largest makers of testosterone-replacement medicines.